Tuesday | Wednesday | Wednesday (OnDemand) | Thursday | Friday

2020 SABCS Virtual Site

Please click here to log into the virtual site
All times are CENTRAL Time
C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX
8:00 am - 10:30 am CT


Moderator: Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

8:00 am CT GS1-01.  Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
                           O'Shaughnessy JA, Johnston S, Harbeck N, Toi M, Im Y-H, Reinisch M, Shao Z, Kellokumpu Lehtinen PL, Huang C-S, Tryakin A, Goetz M, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Steger GG, Del Mastro L, Cox J, Forrester T, Sherwood S, Li X, Wei R, Martin M, Rastogi P. University of Pittsburgh, Pittsburgh, PA; Royal Marsden NHS Foundation Trust, London, United Kingdom; Breast Center, Ludwig-Maximilians-Universität München (LMU), Munich, Germany; Kyoto University Hospital, Kyoto, Japan; Texas Oncology, Dallas, TX; Samsung Medical Center, Seoul, Republic of Korea; Brustzentrum Kliniken Essen-Mitte, Essen, Germany; Fudan University Shanghai Cancer Center, Shanghai, China; Tampere University Hospital TAYS, Tampere, Finland; National Taiwan University Hospital, Taipei, Taiwan; N.N.Blokhin Russian Cancer Research Center, Moscow, Russian Federation; Mayo Clinic, Rochester, MN; UCSF, San Francisco, CA; Medical University of Gdansk, Gdansk, Poland; Clinica Onco Star, Sao Paulo, Brazil; Rigshospitalet, Copenhagen, Denmark; National cancer Center Hospital, Tokyo, Japan;  Medical University of Vienna, Vienna, Austria; Breast Unit, IRCSS Ospedale Policlinico, Università di, Genova, Italy; Eli Lilly and Company, Indianapolis, IN; Hospital General Universitario Gregorio Marañon, Madrid, Spain.  
8:15 am CT GS1-02. Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B  
  Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim S-B, Bear H, Mc Carthy N, Melé Olivé M, Gelmon K, García Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Seiler S, Nekljudova V, Denkert C, Gnant M, Makris A, Burchardi N, von Minckwitz G. German Breast Group, Neu-Isenburg, Germany; UMM-Universitäsklinikum Mannheim, Mannheim, Germany; Instituto de Investigacion Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; Helios Kliniken Berlin-Buch, Berlin, Germany; Institut Bergonié and Université de Bordeaux INSERM U916, Bordeaux, France; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Division of Surgical Oncology, Massey Cancer Center, Virginia Commonwealth University, VCU Health, Richmond, VA; Breast Cancer Trials Australia and New Zealand and University of Queensland, Queensland, Australia; Oncology research group, Hospital Universitario Sant Joan de Reus, Reus, Spain; BC Cancer Agency, Vancouver, BC, Canada; Service de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain; Breast Group, Cancer Trials Ireland, Dublin, Ireland; Department of Obstetrics and Gynecology, University of Rostock, Rostock, Germany; Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Breast Department, UCSF Helen Diller Family Comprehensive Cancer Center, San Franscisco, CA; Institut für Pathologie Philipps-Universität Marburg, Marburg, Germany; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Mount Vernon Cancer Centre, Northwood, United Kingdom.  
 8:30 am CT GS1-03. Discussant
Ruth O'Regan, MD
University of Wisconsin Madison
Madison, WI
 8:45 am CT GS1-04. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies  
  Prat A, Chaudhury A, Solovieff N, Paré L, Martinez D, Chic N, Martínez O, Brasó-Maristany F, Rodriguez-Lorenc K, Taran T, Babbar N, Su F. Hospital Clinic, SOLTI Breast Cancer Research Group, Translational Genomics and Targeted Therapies in Solid Tumors, Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Novartis Institutes for Biomedical Research, Boston, MA; SOLTI Breast Cancer Research Group, Translational Genomics and Targeted Therapies in Solid Tumors, Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Novartis Pharmaceuticals, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland.
9:00 am CT

GS1-05. Hotspot ESR1 mutations rewire cell-cell adhesome to facilitate breast cancer metastasis


Li Z, Wu Y, Bahreini A, Chen J, Qin Y, Levine KM, Tasdemir N, Priedigkeit N, Zhu L, Tseng GC, Jiang Y, Troness B, Buluwela L, Ali S, Arnesen S, Gertz J, Park BH, Zhang Q, Gerratana L, Davis A, Atkinson JM, El-Ashry D2, Cristofanilli M, Lee AV; Oesterreich S. University of Pittsburgh, Pittsburgh, PA; University of Minnesota, Minneapolis, MN; Imperial College London, London, United Kingdom; University of Utah, Salt Lake City, UT; Vanderbilt University, Nashville, TN; Northwestern University, Chicago, IL.

9:15 am CT GS1-06. FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer
  Servetto A, Kollipara R, Formisano L, Lin C-C, Lee K-m, Sudhan DR, Hanker AB, Chatterjee S, Guerrero-Zotano A, Gonzalez-Ericsson P, Mendiratta S, Akamatsu H, James N, Kittler R, Arteaga C. UT Southwestern Medical Center, Dallas, TX; University of Naples "Federico II", Naples, Italy; Instituto Valenciano de Oncología, Valencia, Spain; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Hawaii at Manoa, Manoa, HI.  
9:30 am CT GS1-07.  Treatment persistence of residual breast tumors through an embryonic diapause-like cancer cell state with suppressed Myc activity
                           Dhimolea E, De Matos Simoes R, Kansara D, Bouyssou J, Roth J, Sheffer M, Jeselsohn R, Gray N, Steidl U, Bartholdy B, Brown M, Culhane A, Mitsiades C. Dana Farber Cancer Institute, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Albert Einstein College of Medicine, New York, NY.  
 9:45 am CT GS1-08 The MYC Oncogene Suppresses Tumor Immune Infiltration and Function which is Reversible with Combinatorial Immunotherapies.  
  Lee JV, Housley F, Yau C, Hemmati G, Zhang Y, Samson S, Baas C, Rugo H, Matloubian M, Goga A. UCSF, San Francisco, CA; National Cancer Institute, Bethesda, MD.  
 10:00 am CT GS1-09. Discussant
Thomas "Trey" Westbrook, PhD
Baylor College of Medicine
Houston, TX
 10:15 am CT GS1-10. Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: results of the prospective multicenter RISAS trial  
  Simons JM, v Nijnatten TJA, Koppert LB, van der Pol CC, v Diest PJ, A Jager, v Klaveren D, Kam BLR, Lobbes MBI, de Boer M, Verhoef C, Sars PRA, Heijmans HJ, van Haaren ERM, Vles WJ, Menke, MBE Smit LHM, Kelder W, Boskamp M, Mares-Engelberts I, Luiten EJT, Smidt ML.  
10:40 am - 11:15 am CT WILLIAM L. MCGUIRE MEMORIAL LECTURE supported by GlaxoSmithKline Oncology (GSK)
Mary-Claire King, PhD
University of Washington
Seattle, WA
10:00 am - 3:00 pm CT Exhibits  
11:30 am - 1:00 pm  CT CAREER DEVELOPMENT FORUM, sponsored by Eisai, Inc.
  The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2020 SABCS®
  The Career Roundtables provide interactive informational interviews with experts on a variety of topics that are important for career development of early-career scientists. The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2020 SABCS.  

The Virtual Career Roundtables will have 2, 40-minute sessions. The same 13 topics will be available for both sessions. At the end of the first session you will be asked to exit and rotate to a new topic/room. You do not need to attend both sessions. 

Each breakout room is limited to a total of 25 participants, inclusive of 3 mentors (2 scientists and 1 patient advocate). Attendance for each breakout room will be on a first-come, first-served basis. Please identify alternative room topics in the event your first-choice room is full. Please join with your full name listed, camera on, but audio muted until you are ready to ask a question.

Some breakout room topics will have a more clinical focus, while others will have a more laboratory research focus. The subthemes are denoted in parenthesis after the breakout room topic name.
11:25 am - 11:35 am CT Introduction
11:30 am  Whereby Video Conference Rooms Open  
11:35 am - 12:15 pm CT Breakout Session 1  
12:15 pm - 12:20 pm CT Mid-Session Announcement
12:20 pm - 1:00 pm CT  Breakout Session 2
  Roundtable Topics   

1.     Balancing Research and Clinical Practice (Clinical)
        Cynthia Ma, Washington University Siteman Cancer Center, St. Louis, MO
        Seema Khan, Northwestern University, Chicago, IL
        Thelma Brown, Susan G. Komen – Advocate
2.     How to Engage Clinicians in Your Research (Laboratory)
        Rachel Schiff, Baylor College of Medicine, Houston, TX
        Doug Yee, University of Minnesota, Minneapolis, MN
        Teri Pollastro, Metastatic Breast Cancer Alliance – Advocate
3.     Becoming a Successful Clinical Trialist (Clinical)
        Kathy Miller, Indiana University School of Medicine, Indianapolis, IN
        Rita Nanda, University of Chicago, Chicago, IL
        Coleen Crespo, Sisters Network Triangle, Alliance for Clinical Trials in
        Oncology – Advocate, UNC Lineberger Comprehensive Cancer Center - Advocate
4.     Careers in Industry I
        Ahmed Samatar, Zentalis Pharmaceuticals, New York, NY
        Paul Haluska, Bristol-Myers Squibb, Princeton, NJ
        Patty Spears, UNC Lineberger Comprehensive Cancer Center-Advocate
5.     Careers in Industry II
        Lori Friedman, ORIC Pharmaceuticals, San Carlos, CA
        Maura Dickler, Eli Lilly and Company, New York, NY          
        Meryl Weinreb, Susan G. Komen – Advocate
6.     Careers in Translational Research (Clinical)
        Aditya Bardia, Massachusetts General Hospital, Boston, MA
        Ian Krop, Dana-Farber Cancer Institute, Boston, MA
        Christine Hodgdon, GRASP Cancer – Advocate
7.     Careers in Translational Research (Laboratory)
        Ben Park, Vanderbilt-Ingram Cancer Center, Nashville, TN
        Nicholas C. Turner, Royal Marsden Hospital Institute of Cancer Research,
        London, England         
        Roberta Albany, Living Beyond Breast Cancer –  Advocate
8.     Funding Your Own Research
        Yi Li, Baylor College of Medicine, Houston, TX
        Elizabeth Mittendorf, Dana-Farber Cancer Institute, Boston, MA
        Dorothy Paterson, MD Anderson Cancer Center – Advocate
9.     Making the Transition from Fellowship to Faculty (Clinical)
        Dawn L. Hershman, Columbia University, New York, NY
        Matt Goetz, Mayo Clinic College of Medicine, Rochester, MN
        Jeannine Salamone, Georgetown Breast Cancer Advocates – Advocate
10.   Making the Transition from Fellowship to Faculty (Laboratory)  
        Adrian Lee, University of Pittsburgh, Pittsburgh, PA
        Alana Welm, University of Utah Huntsman Cancer Institute, Salt Lake City,
        Debbie Setuain, FORCE - Facing Hereditary Cancer EMPOWERED –
11.   Negotiating a Job Offer or Promotion
        Reshma Jagsi, University of Michigan, Anne Arbor, MI
        Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA
        Anne Meyn, Susan G. Komen – Advocate
12.  Team Science: Values, Challenges, and How to Get Started
       Chuck Perou, University of North Carolina, Chapel Hill, NC
       Nancy E. Davidson, Fred Hutchinson Cancer Research Center, Seattle, WA
       Cheryl Jernigan, Susan G. Komen – Advocate
13.  Strategizing Your Academic Career Path (Time Commitments, Grants,
       Publications & More

        Mark E. Robson, Memorial Sloan Kettering Cancer Center, New York NY       
        Xiang (Shawn) Zhang, Baylor College of Medicine, Houston, TX
        Ghecemy Lopez, National Breast Cancer Coalition – Advocate
11:30 am - 1:00 pm CT CASE DISCUSSION 1
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
  Panel Members
Vernal Branch
Alamo Breast Cancer Foundation
San Antonio, TX

Charlotte Coles
Cambridge University
Cambridge, United Kingdom

Sara Hurvitz, MD FACP
University of California
Los Angeles, CA

Roshni Rao, MD
Columbia University
New York, NY

Karla Sepulveda, MD
Baylor College of Medicine
Houston, TX

Eric P. Winer, MD
Dana-Farber Cancer Center
Boston, MA
1:00 pm - 4:00 pm CT


Moderator: Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

1:00 pm CT GS2-01. The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ  

Harismendy O, Nachmanson D, Evans MF, Mori H, Officer A, Yau C, Steward J, Yao H, O'Keefe T, Hasteh F, Stein GS, Jepsen K, Campbell M, Weaver DL, Hirst GL, Sprague BL, Esserman LJ, Gordon JA, Borowsky A, Stein JL. UC San Diego, San Diego, CA; University of Vermont, Burlington, VT; UC Davis, Davis, CA; UC San Francisco, San Francisco, CA.

1:15 pm CT GS2-02. 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ  
  Sestak I, Cuzick J, Bonanni B, Bundred N, Levy C, Loib S, Neven P, Stierer M, Holcombe C, Coleman R, Forbes J, Howell A. Centre for Cancer Prevention, London, United Kingdom; Istituto Europeo di Oncologia, Milan, Italy; University of Manchester, Manchester, United Kingdom; Centre François Baclesse, Caen, France; German Breast Group, Frankfurt, Germany; UZ Leuven, Leuven, Belgium; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Royal Liverpool University Hospital, Liverpool, United Kingdom; University of Sheffield, Sheffield, United Kingdom; Breast Cancer Trials, Newcastle, Australia.  
1:30 pm CT GS2-03. Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in women =/> 65 years with early invasive breast cancer:10 year results
  Kunkler IH, Williams LJ, Jack W, Cameron DA, Dixon M. University of Edinburgh, Institute of Genetics and Molecular Medicine, United Kingdom; Usher Institute, Edinburgh University, Edinburgh, United Kingdom; Western General Hospital, Edinburgh, United Kingdom.  
1:45 pm CT GS2-04. A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)
  Chua BH, Link E, Kunkler I, Olivotto I, Westenberg AH, Whelan T, Gruber G, Breast International Group (BIG)-aisbl, Trans Tasman Radiation Oncology Group, Scottish Cancer Trials Breast Group, Canadian Cancer Trials Group, European Organization for Research and Treatment of Cancer, International Breast Cancer Study Group, Cancer Trials Ireland. University of New South Wales, Sydney, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; University of Edinburgh, Edinburgh, United Kingdom; University of Calgary, Calgary, AB, Canada; Radiotherapiegroep Arnhem, Arnhem, Netherlands; McMaster University, Hamilton, ON, Canada; Klinik Hirslanden, Institute for Radiotherapy, Zurich, Switzerland.  
 2:00 pm CT GS2-05 Genome-wide association study identifies UACA as a modulator of breast cancer chemoresistance and survival  
  Kushi LH, Zhu Q, Schultz E, Long J, Roh JM, Valice E, Laurent CA, Yan L, Ergas IJ, Davis W, Ranatunga DK, Kwan ML, Bao P-P, Zheng W, Shu X-O, Ambrosone CB, Yao S. Kaiser Permanente Northern California, Oakland, CA; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Vanderbilt University Medical Center, Nashville, TN; Shanghai Municipal Center for Disease Prevention and Control, Shanghai, China.   
2:15 pm CT GS2-06. Exploring the causal role of the Human Gut Microbiome in Breast Cancer Risk using Mendelian Randomization  
                           Robinson T, Edmunds G, Hayes B, Wade K. University of Bristol, Bristol, United Kingdom
2:30 pm CT GS2-07. Glycemic Index, Glycemic Load and breast cancer risk: results from the prospective NutriNet-Santé cohort
  Debras C, Chazelas E, Srour B, Julia C, Kesse-Guyot E, Zelek L, Agaësse C, Druesne-Pecollo N, Galan P, Hercberg S, Latino-Martel P, Deschasaux M, Touvier M. Nutritional epidemiology Research Team (Inserm, Inra, Cnam, Paris 13 University), Bobigny, France; Oncology Department, Avicenne Hospital, AP-HP, Bobigny, France.  
2:45 pm CT GS2-08. Discussant
Marian L. Neuhouser, PhD, RD
Fred Hutchinson Cancer Research Center
Seattle, WA
3:00 pm CT GS2-09. Diabetes risk reduction diet and survival following breast cancer  
  Wang T, Farvid M, Kang JH, Holmes M, Rosner B, Tamimi R, Willett W, Eliassen AH. Brigham & Women’s Hospital, Harvard Medical School, and Harvard T. H. Chan School of Public Health, Boston, MA; Harvard T. H. Chan School of Public Health, Boston, MA; Brigham & Women’s Hospital and Harvard Medical School, Boston, MA; Weill Cornell Medicine and Harvard T. H. Chan School of Public Health, New York, NY.  
3:15 pm CT GS2-10. Targeting depressive symptoms in younger breast cancer survivors: A randomized controlled trial of mindfulness mediation and survivorship education  
  Ganz P, Bower JE, Partridge AH, Wolff AC, Thorner ED, Joffe H, Irwin MR, Petersen L, Petersen L, Crespi CM. Department of Health Policy & Management, UCLA Fielding School of Public Health, Los Angeles, CA; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA  
3:30 pm CT BREAK  
4:00 pm - 5:15 pm CT

SPOTLIGHT SESSION 1: Novel Therapeutics


Chair: Claudine Isaacs, MD
Georgetown University
Washington, DC

Improving endocrine therapy
Cristina Saura Manich, MD, PhD
Hospital Vall d'Hebron Barcelona
Barcelona, Spain

Novel targets
Bora Lim, MD
UT MD Anderson Cancer Center
Houston, TX

5:15 pm - 6:30 pm CT SPOTLIGHT SESSION 2: Refining Targeted Therapy in Hormone Receptor Breast Cancer

Chair: Hope S. Rugo, MD, FASCO
University California San Francisco
San Francisco, CA

Newer targeted agents and NGS in metastatic disease
Maria Vittoria Dieci
University of Padova
Padova, Italy

CDK4/6 inhibitor in early and late stage disease
Amy Clark, MD
University of Pennsylvania
Philadelphia, PA

Predictive biomarkers in hormone receptor positive breast cancer
Luca Malorni, MD, PhD
Hospital of Prato
Prato, Italy

6:30 pm - 7:45 pm CT SPOTLIGHT SESSION 3: Advances in the Treatment of HER2+ Disease

Chair: Adam Brufsky, MD
University of Pittsburgh
Pittsburgh, PA

Biomarkers and disease characteristics to predict response and resistance to HER2 targeted therapy
Guiseppe Curigliano, MD
Instituto Europeo di Oncologia
Milano, Italy

Oral tyrosine kinase inhibitors and ADCs in HER2+ breast cancer
Tiffany Traina, MD
Memorial Sloan Kettering Cancer Center
New York, NY

De-escalating therapy in early and late stage disease, and continuing antibody therapy post progression
Rashmi Krishna Murthy, MD
UT MD Anderson Cancer Center
Houston, TX

7:30 pm CT

OPEN SATELLITE EVENT presented by Physicians' Education Resource, LLC

Navigating Treatment Options for HER2+ Breast Cancer Across the Disease Continuum: An Expert Tumor Board Discussion

For more information and to register for this event, click on the link below:

Tuesday | Wednesday | Wednesday (OnDemand) | Thursday | Friday



Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Tuesday | Wednesday | Wednesday (OnDemand) | Thursday | Friday
In collaboration with  Astro     and     SSO